报价延迟最少15分钟:2026/03/09 20:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
146.63 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
6.78/9.35
|
|
企业价值
200.81B
|
| 资产负债 |
|
每股账面净值
18.29
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
29.44B
|
|
每股收益
22.06
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
